UTMDMEDIUM SIGNALFINANCIAL10-K

UTMD showed declining profitability with operating income falling 16.1% while substantially reducing share repurchases and improving its balance sheet position.

The combination of lower operating income and reduced share buyback activity suggests management may be conserving cash in response to operational headwinds. However, the significant reduction in total liabilities and improved balance sheet metrics indicate stronger financial positioning despite near-term profitability challenges.

Comparing 2026-03-27 vs 2025-03-26View on EDGAR →
FINANCIAL ANALYSIS

UTMD's financial performance reflects a mixed picture with operating income declining 16.1% to $11.4M while the company substantially reduced interest expense and R&D spending. Share repurchases fell meaningfully from $20.0M to $8.4M, signaling a more conservative capital allocation approach. The balance sheet strengthened notably with total liabilities declining 35.9% and current liabilities falling 30.8%, positioning the company with improved financial flexibility despite operational pressures.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-77.5%
$289K$65K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Capital Expenditure
Cash Flow
+61.3%
$230K$371K

Capital expenditure jumped 61.3% — major investment cycle underway; assess returns on deployment.

Share Buybacks
Cash Flow
-58.2%
$20.0M$8.4M

Buyback activity reduced 58.2% — capital being redeployed elsewhere or cash conservation underway.

Total Liabilities
Balance Sheet
-35.9%
$5.1M$3.3M

Liabilities reduced 35.9% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-30.8%
$3.8M$2.6M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-17.8%
$813K$668K

R&D spending cut 17.8% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-16.1%
$13.6M$11.4M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

Accounts Receivable
Balance Sheet
-14%
$4.1M$3.5M

Receivables declined — improved collection efficiency or conservative revenue recognition.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-26
ADDED
As of June 30, 2025, the aggregate market value of the voting and nonvoting common equity held by non-affiliates of the registrant was $ 168,203,211 .
As of March 26, 2026, common shares outstanding are 3,185,025 .
The opportunity to apply solutions to recognized needs results from a core of practicing clinicians who introduce ideas to the Company, together with key employees who are both clinical applications savvy and development engineering adept.
Domestically, UTMD s medical devices are sold directly to clinical end-user facilities or designated stocking distributors for medical facilities.
UTMD has representation globally in the major developed countries as well as many underdeveloped countries through approximately 200 OUS distributors, 108 of which purchased at least five thousand dollars in UTMD medical devices during 2025.
+7 more — sign up free →
REMOVED
As of June 30, 2024, the aggregate market value of the voting and nonvoting common equity held by non-affiliates of the registrant was $ 216,013,098 .
As of March 25, 2025, common shares outstanding are 3,281,816 .
The opportunity to apply solutions to recognized needs results from an excellent core of practicing clinicians who introduce ideas to the Company, and key employees who are both clinical applications savvy and development engineering adept.
Domestically, UTMD s medical devices are sold directly to clinician end-user facilities or a designated stocking distributor for a medical facility.
UTMD has representation globally in the major developed countries as well as many underdeveloped countries through approximately 200 distributors, 104 of which purchased at least five thousand dollars in UTMD medical devices during 2024.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →